Table 2.
Ongoing clinical trials designed to investigate the effect of dietary and probiotics interventions on immunotherapy for NSCLC.
| NCT number | Patient (n) |
Study Title | Intervention | Research purpose | Enrollment status |
|---|---|---|---|---|---|
| NCT03700437 | 12 | Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC). | Fasting-mimicking diet | Evaluate the effect of the fasting-mimicking diet therapy on chemotherapy combined with immunotherapy in NSCLC. | Completed |
| NCT04924374 | 20 | Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy. | High-fiber diets | Evaluate the effect of gut microbiota in patients with a high-fiber diet on the efficacy of immunotherapy in patients with advanced NSCLC. | Recruiting |
| NCT04175769 | 60 | A Nutritional Supplement to Support People With Non-small Cell Lung Cancer. | Nutritional supplement | Evaluate the effect of nutritional products on the response of patients to immunotherapy or immunotherapy combined with chemotherapy in NSCLC. | Recruiting |
| NCT05902260 | 50 | The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC. | Nutritional intervention | Evaluate the effect of high-energy/high-protein nutritional supplements on anti–PD-1 therapy for NSCLC. | Recruiting |
| NCT05384873 | 180 | Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer. | High-calorie-high-protein nutritional liquid supplement enriched in immunonutrients | Evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in NSCLC patients undergoing immunotherapy and receiving nutritional counseling. | Recruiting |
| NCT05865730 | 122 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors. | Live Bacterial Product - Akkermansia muciniphila (Oncobax®-AK) | Prove that the oral administration of Oncobax®-AK to cancer patients under immunotherapy, but whose gut microbiota is deficient in Akkermansia will restore/improve the efficacy of immunotherapy in patients with NSCLC or RCC. | Recruiting |
| NCT05303493 | 45 | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma. | Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) | Assess the safety and tolerability of Camu Camu prebiotic in patients with advanced NSCLC and melanoma in combination with standard-of-care ICI. | Recruiting |
| NCT04699721 | 40 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC. | Bifidobacterium trifidum live powder | Evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for early resectable NSCLC patients. | Active, not recruiting |
| NCT05094167 | 46 | Lactobacillus Bifidobacterium V9 (Kex02) Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients. | Lactobacillus Bifidobacterium V9 | Evaluate the efficacy of probiotics Bifidobacterium Lactobacillus V9 (Kex02) in the treatment of NSCLC with lizumab combined with platinum. | Recruiting |
PD-1, programmed cell death 1; NSCLC, non–small cell lung cancer.